Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 209

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 209
---
                             | 6.1 |     |                           | - |
| Grants                                           |     |                   |    740,000 |   |     |          |  0.3 |     |                             |  10 |     |                           | - |
| Exercised                                        |     |                   | (2,800,000 | ) |     |          |      |     |                             |     |     |                           |   |
| Outstanding at December 31, 2024                 |     |                   |  4,960,000 |   |     |          |  0.3 |     |                             | 6.1 |     |                           | - |
| Vested and expected to vest at December 31, 2024 |     |                   |  4,960,000 |   |     |          |  0.3 |     |                             | 6.1 |     |                           | - |
| Exercisable at December 31, 2024                 |     |                   |  3,790,000 |   |     |          | 0.38 |     |                             | 5.1 |     |                           | - |

<div align='center'>F-29</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 9 – TAXES ON INCOME

| a. | Tax rates applicable to the Company: |

Taxable income
of the Company is subject to the US Corporate tax rate, which was 21% in 2024 and 2023. At December 31, 2024, the Company had U.S. federal
net operating loss carryforwards of approximately $1,074 available to reduce future taxable income.

| b. | Tax rates applicable to the Subsidiary: |

Taxable income
of the Subsidiary is subject to the Israeli Corporate tax rate, which was 23% in 2024 and 2023.

The Company’s
Israeli subsidiaries have estimated total available carryforward operating tax losses for Israeli income tax purposes of approximately
$4,460 as of December 31, 2024.

| c. | The Subsidiaries have not received final tax assessment since its inception. |

| d. | Deferred income taxes: |

As of December
31, 2024, July 23, 2024 and December